natgillin/translations-raw huggingface dataset:
Days of disability 
Število dni nezmožnosti
Therefore, interactions resulting from displacement of highly proteinbound drugs are unlikely. 
Zato interakcije, ki se kažejo kot izrivanje zdravil pretežno vezanih na beljakovine, niso verjetne.
It is prudent to avoid dental surgery as recovery may be prolonged (see section 4.4). 
Smiselno se je izogibati kirurškim posegom na zobeh, saj lahko podaljšajo čas okrevanja (glejte poglavje 4.4).
Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker. 
Veliko bolnikov z osteoporozo ne čuti nobenih simptomov, kljub temu pa pri njih obstaja nevarnost, da si zlomijo kosti, ker so njihove kosti zaradi osteoporoze bolj krhke.
At least one new vertebral fracture (0-1 year) At least one new vertebral fracture (0-2 year) At least one new vertebral fracture (0-3 year) ** p <0.0001 
vsaj en nov zlom vretenca (v prvem letu) vsaj en nov zlom vretenca (v prvih dveh letih) vsaj en nov zlom vretenca (v prvih treh letih) ** p <0,0001
At the menopause, a woman's ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. 
Pri ženski po menopavzi jajčniki ne tvorijo več ženskega hormona estrogena, ki pomaga ohranjati kosti zdrave.
This will help to prevent dehydration. 
Pitje bo pomagalo preprečiti dehidracijo.
These results were consistent with biochemical marker evidence of normalisation of bone turnover. 
Dobljeni rezultati so se skladali z dokazi biokemijskih označevalcev normalizacije pregradnje kosti.
All clinical fractures were verified based on the radiographic and/or clinical evidence. 
Učinek na vse klinične zlome Vsi klinični zlomi so bili dokazani radiografsko in/ali na podlagi kliničnih znakov.
This is especially important for the elderly and for patients receiving diuretic therapy. 
To je posebno pomembno za starejše in za bolnike, ki jemljejo tudi diuretike.
Before you receive treatment with Zoledronic acid Teva Generics, tell your doctor if you have (or have had) pain, swelling or numbness in your gums, jaw or both, if your jaw feels heavy, or if you have lost a tooth. 
Preden začnete zdravljenje z zdravilom Zoledronska kislina Teva Generics, zdravniku povejte, če imate (ali ste imeli kdaj prej) bolečino, oteklino ali občutek odrevenelosti v dlesnih, v čeljusti ali v obojem, če čutite težo v čeljusti ali vam je izpadel zob.
EXP After opening: 24 hours at 2°C - 8°C 
EXP: Po odprtju: 24 ur pri 2 °C - 8 °C.
• in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture. 
• pri odraslih moških s povečanim tveganjem za zlome vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
Patients with hepatic impairment No dose adjustment is required (see section 5.2). 
Bolniki z jetrno okvaro Prilagajanje odmerjanja ni potrebno (glejte poglavje 5.2).
Placebo (N = 1,062) event rate 
Izid placebo (N=1.062) delež dogodkov (%)
After 6 months, zoledronic acid showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p<0.001). 
Po 6 mesecih je zoledronska kislina pokazala 96-odstotno (169/176) oziroma 89-odstotno odzivnost (156/176) oziroma pogostost normalizacije vrednosti serumske alkalne fosfataze (SAP) v primerjavi s 74 % (127/171) oziroma 58 % (99/171) pri risedronatu (v vseh primerih p <0,001).
Uncommon Hypertension, flushing Not known** Hypotension (some of the patients had underlying risk factors) 
Žilne bolezni hipertenzija, navali rdečice neznana** hipotenzija (pri nekaterih od teh bolnikov so bili že prej prisotni dejavniki tveganja)
The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with zoledronic acid versus 8.7% for placebo. 
S študijo ni bilo mogoče pokazati zmanjšanja obsega kliničnih zlomov pri moških; incidenca kliničnih zlomov je bila pri moških, zdravljenih z zoledronsko kislino, 7,5 % v primerjavi z 8,7 % pri uporabi placeba.
Hypocalcaemia* Uncommon Anorexia, decreased appetite 
občasni anoreksija, zmanjšan apetit
It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with steroids, and Paget's disease of the bone in adults. 
Pripada skupini zdravil, ki se imenujejo difosfonati in jih uporabljamo za zdravljenje postmenopavzalnih žensk in odraslih moških z osteoporozo ali z osteoporozo zaradi zdravljenja s steroidi in s Pagetovo boleznijo kosti pri odraslih.
Clinical efficacy in the treatment of osteoporosis in patients at increased risk of fracture after a recent hip fracture (RFT) 
Klinična učinkovitost pri zdravljenju osteoporoze pri bolnikih s povečanim tveganjem za zlome po nedavnem zlomu kolka (RFT)
The medicinal product must not be mixed or given intravenously with any other medicinal products. 
Tega zdravila ne smete mešati ali dajati intravensko skupaj z drugimi zdravili.
Limited data on re-treatment of Paget's disease are available (see section 5.1). 
O ponovnem zdravljenju Pagetove bolezni je na voljo omejeno število podatkov (glejte poglavje 5.1).
In a large clinical trial, local reactions at the infusion site, such as redness, swelling and/or pain, were reported (0.7%) following the administration of zoledronic acid. 
V obsežnem kliničnem preskušanju so poročali o lokalnih reakcijah, kot so rdečina, oteklina in/ali bolečina (0,7 %), po odmerjanju zoledronske kisline.
This leaflet was last revised in {MM/YYYY} 
Navodilo je bilo nazadnje revidirano dne {MM/YYYY} Drugi viri informacij
Zoledronic acid demonstrated a consistent effect over 3 years, resulting in a 41% reduction in the risk of hip fractures (95% CI, 17% to 58%). 
Učinek na zlome kolkov Zoledronska kislina je pokazala stalen učinek v obdobju 3 let, kar je omogočilo 41-odstotno znižanje tveganja za zlom kolkov (95 % IZ: 17 % do 58 %).
The primary efficacy variable was the incidence of clinical fractures over the duration of the study. 
Primarna spremenljivka za oceno učinkovitosti je bila incidenca kliničnih zlomov v celotnem poteku študije.
Since zoledronic acid is not metabolised in humans and the substance was found to have little or no capacity as a direct-acting and/or irreversible metabolism-dependent inhibitor of P450 enzymes, zoledronic acid is unlikely to reduce the metabolic clearance of substances which are metabolised via the cytochrome P450 enzyme systems. 
Ker človek ne presnavlja zoledronske kisline in ker so ugotovili, da ta zdravilna učinkovina v manjši meri ali pa sploh ne deluje kot neposredno delujoči in/ali ireverzibilni, od presnove odvisni, zaviralec encimov P450, ni verjetno, da bi zoledronska kislina zmanjšala presnovni očistek snovi, ki se presnavljajo prek encimskega sistema citokrom P450.
36 months. 
15 minut.
What you need to know before you are given Zoledronic acid Teva Generics Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given Zoledronic acid Teva Generics. 
Kaj morate vedeti, preden vam dajo zdravilo Zoledronska kislina Teva Generics Skrbno se ravnajte po vseh navodilih zdravnika, farmacevta ali medicinske sestre, preden vam dajo zdravilo Zoledronska kislina Teva Generics.
In Paget's disease, bone remodelling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal. 
Pri Pagetovi bolezni je kostna pregradnja prehitra, nova kostnina pa se tvori nepravilno, zato je šibkejša od normalne.
Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of zoledronic acid (see section 4.8). 
Zaradi hitrega začetka delovanja zoledronske kisline na pregradnjo kosti se utegne razviti prehodna hipokalciemija, ki je včasih simptomatska in ki je navadno najbolj izražena v prvih 10 dneh po infuziji zoledronske kisline (glejte poglavje 4.8).
It is unknown whether zoledronic acid is excreted into human milk. 
Ni znano, ali se zoledronska kislina izloča v materino mleko pri ljudeh.
A summary of results is presented in Table 3. 
Pregled izsledkov je prikazan v preglednici 3.
Your doctor will advise you and decide how long you should be treated with Zoledronic acid Teva Generics. 
Zdravnik vam bo svetoval in presodil, kako dolgo bi se morali zdraviti z zdravilom Zoledronska kislina Teva Generics.
Decreased circulating levels of sex hormones, mainly oestrogens converted from androgens, also play a role in the more gradual bone loss observed in men. 
Tudi znižanje koncentracij spolnih hormonov v krvnem obtoku, predvsem estrogenov, ki se pretvorijo iz androgenov, ima pomembno vlogo pri postopnejšem izgubljanju kostnine pri moških.
Swelling, redness, pain and itching to the eyes or eye sensitivity to light. 
Otekanje, rdečina, bolečina in srbenje v očeh ali povečana občutljivost oči za svetlobo.
Effect on height 
Učinek na telesno višino
Your doctor, pharmacist or nurse knows how to store Zoledronic acid Teva Generics properly. 
Vaš zdravnik, farmacevt in medicinska sestra vedo, kako je treba zdravilo Zoledronska kislina Teva Generics pravilno shranjevati.
The incidence of delayed hip fracture healing was comparable between zoledronic acid (34 [3.2%]) and placebo (29 [2.7%]). 
Incidenca zakasnitve celjenja zloma kolka je bila primerljiva med skupinama z zoledronsko kislino (34 [3,2 %]) oziroma s placebom (29 [2,7 %]).
In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidney may increase. 
Pri bolnikih z okvaro ledvic lahko pride do povečane sistemske izpostavljenosti spremljajočim zdravilom, ki se izločajo predvsem preko ledvic.
Thereafter bone markers stabilised within the pre-menopausal range. 
Po tem so se vrednosti kostnih označevalcev stabilizirale v premenopavzalnem okviru.
Five of the 6 patients had SAP within the normal range at month 6 (Last Observation Carried Forward, LOCF). 
Pri petih od teh šestih bolnikov je bila vrednost alkalne fosfataze v serumu po 6 mesecih v okviru normalnih vrednosti (po principu zadnje izmerjene vrednosti prenesene naprej (Last Observation Carried Forward, LOCF)).
Aseptic techniques must be followed during preparation of the infusion. 
Med pripravo infuzije uporabljajte aseptične tehnike.
Teratogenicity was observed in rats at doses ≥ 0.2 mg/kg and was manifested by external, visceral and skeletal malformations. 
Teratogenost so ugotovili pri podganah v odmerkih ≥ 0,2 mg/kg, ki se je kazala v obliki zunanjih, visceralnih in skeletnih malformacij.
Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely. 
Zoledronska kislina se ne veže v veliki meri na beljakovine plazme (vezana je približno v 43-55 %), zato interakcije, ki se kažejo kot izrinjanje zdravil pretežno vezanih na beljakovine, niso verjetne.
Not known** Hypersensitivity reactions including rare cases of bronchoconstriction, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock 
preobčutljivostne reakcije, vključno z redkimi primeri bronhospazma, urtikarije in angioedema in z zelo redkimi primeri anafilaktične reakcije/šoka
In another study in men (study CZOL446M2308) an annual infusion of zoledronic acid was non-inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline. 
V drugi študiji z moškimi (študija CZOL446M2308) letna infuzija zoledronske kisline ni bila slabša od tedenske uporabe alendronata glede odstotka spremembe mineralne gostote kosti ledvene hrbtenice po 24 mesecih v primerjavi z izhodiščem.
After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels. 
Po začetku infundiranja zoledronske kisline so se koncentracije zdravilne učinkovine v plazmi hitro zvišale, dosegle ob koncu infundiranja vrh, ki mu je sledilo hitro znižanje na <10 % najvišje dosežene vrednosti po 4 urah in na <1 % najvišje dosežene vrednosti po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki niso presegle 0,1 % najvišje vrednosti.
The incidence of clinical fractures, including vertebral, non-vertebral and hip fractures, was evaluated in 2,127 men and women aged 50-95 years (mean age 74.5 years) with a recent (within 90 days) low-trauma hip fracture who were followed for an average of 2 years on study medication. 
Incidenco kliničnih zlomov, vključno z zlomi vretenc, nevretenčnimi zlomi in zlomi kolka, so vrednotili pri 2.127 moških in ženskah, starih 50-95 let (povprečna starost 74,5 let) z nedavnim (v okviru 90 dni) zlomom kolka po lažji poškodbi, ki so jih opazovali povprečno 2 leti med zdravljenjem s študijskim zdravilom.
In case you recently broke your hip, it is recommended that Zoledronic acid Teva Generics is administered two or more weeks after your hip repair surgery. 
Če ste si pred kratkim zlomili kolk, je priporočljivo, da dobite zdravilo Zoledronska kislina Teva Generics dva ali več tednov po operativnem zdravljenju kolka.
Effect on all clinical fractures The incidence rates of key clinical fracture variables are presented in Table 4. 
Učinek na vse klinične zlome Stopnje incidenc ključnih kliničnih zlomov so prikazane v preglednici 4.
Elevated bone turnover is a characteristic of Paget's disease of the bone. 
Povečana pregradnja kosti je značilnost Pagetove bolezni kosti.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Študij medsebojnega delovanja z drugimi zdravili niso izvedli.
In both women and men, Zoledronic acid Teva Generics strengthens the bone and therefore makes it less likely to break. 
Tako pri ženskah kot pri moških zdravilo Zoledronska kislina Teva Generics okrepi kosti in tako zmanjša verjetnost zlomov.
The use of Zoledronic acid Teva Generics in children and adolescents has not been studied. 
Uporabe zdravila Zoledronska kislina Teva Generics pri otrocih in mladostnikih niso proučevali.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in Paget's disease of the bone, osteoporosis in post-menopausal women at an increased risk of fracture, osteoporosis in men at increased risk of fracture and prevention of clinical fractures after a hip fracture in men and women (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij referenčnega zdravila, ki vsebuje zoledronsko kislino za vse skupine pediatrične populacije s Pagetovo boleznijo kosti, za osteoporozo pri postmenopavzalnih ženskah s povečanim tveganjem za zlome, za osteoporozo pri moških s povečanim tveganjem za zlome in za preprečevanje kliničnih zlomov po zlomu kolka pri ženskah in moških (za podatke o uporabi pri pediatrični populaciji glejte poglavje
The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid Teva Generics. 
Večina neželenih učinkov, kot so vročina z mrzlico, bolečine v mišicah in sklepih in glavobol, nastopi v prvih treh dneh po odmerku zdravila Zoledronska kislina
Zoledronic acid Teva Generics must not be mixed or given intravenously with any other medicinal product and must be given through a separate vented infusion line at a constant infusion rate. 
Zdravila Zoledronska kislina Teva Generics ne smete mešati ali dajati intravensko z drugim zdravilom, dajati ga morate po ločenem prezračevanem infuzijskem sistemu s stalno hitrostjo infundiranja.
- Do not use this medicine if you notice any discolouration or particles in the solution. 
- Ne uporabljajte tega zdravila, če opazite, da je raztopina drugačne barve ali so v njej majhni
If you feel dizzy while taking Zoledronic acid Teva Generics, do not drive or use machines until you feel better. 
Če ste v obdobju zdravljenja z zdravilom Zoledronska kislina Teva Generics omotični, ne vozite in ne upravljajte strojev, dokler se vaše počutje ne izboljša.
Re-treatment of Paget's disease: After initial treatment with zoledronic acid in Paget's disease an extended remission period is observed in responding patients. 
Ponovno zdravljenje Pagetove bolezni: Po začetnem zdravljenju Pagetove bolezni z zoledronsko kislino opažajo pri bolnikih, ki se odzovejo na zdravljenje, obdobje dolgotrajne remisije.
The study was not powered to show a reduction in clinical fractures compared to risedronate. 
S študijo ni bilo mogoče pokazati manjše pogostnosti kliničnih zlomov v primerjavi z uporabo risedronata.
All cause mortality was 10% (101 patients) in the zoledronic acid-treated group compared to 13% (141 patients) in the placebo group. 
Umrljivost iz kateregakoli vzroka je bila 10 % v skupini, zdravljeni z zoledronsko kislino (101 bolnik), v primerjavi s 13 % v skupini s placebom (141 bolnikov).
The early disposition phases (α and β, with t½ values above) presumably represent rapid uptake into bone and excretion via the kidneys. 
Obe zgodnji obdobji prisotnosti zdravila v obtoku (α in β, z zgoraj navedenima vrednostima t½) sta po vsej verjetnosti obdobji hitrega privzema v kostnino in izločanja preko ledvic.
In the osteoporosis trials (PFT, HORIZON - Recurrent Fracture Trial [RFT]) the pooled atrial fibrillation incidences were comparable between zoledronic acid (2.6%) and placebo (2.1%). 
V študijah osteoporoze (v PFT, v študiji HORIZON - študiji ponovnih zlomov (Recurrent Fracture Trial [RFT]) sta bili združeni incidenci atrijske fibrilacije primerljivi med zoledronsko kislino (2,6 %) in placebom (2,1 %).
• Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non smoking and healthy diet 
• kontraindikacije med nosečnostjo in dojenjem, • potrebnost zadostnega nadomeščanja kalcija in vitamina D, ustrezne telesne dejavnosti in zdrave prehrane ter odsotnosti kajenja,
For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg zoledronic acid administered once a year. 
Osteoporoza Za zdravljenje postmenopavzalne osteoporoze, osteoporoze pri moških in osteoporoze zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi je priporočeni odmerek ena intravenska infuzija s 5 mg zoledronske kisline enkrat na leto.
If you missed a dose of Zoledronic acid Teva Generics Contact your doctor or hospital as soon as possible to re-schedule your appointment. 
Če ste izpustili odmerek zdravila Zoledronska kislina Teva Generics Čimprej pokličite zdravnika oziroma v bolnišnico, da se dogovorite za nov datum.
Zoledronic acid treatment rapidly reduced the rate of bone turnover from elevated post-menopausal levels with the nadir for resorption markers observed at 7 days, and for formation markers at 12 weeks. 
Zdravljenje z zoledronsko kislino je hitro znižalo stopnjo pregradnje kosti z zvišanih postmenopavzalnih vrednosti; vrednosti označevalcev resorpcije so bile najnižje po 7 dneh, vrednosti označevalcev nastajanja kosti pa po 12 tednih.
During this entire time period bone turnover markers were within the pre-menopausal range at the end of each year. 
V celotnem obdobju so bile ob koncu vsakega leta vrednosti označevalcev pregradnje kosti v okviru premenopavzalnih vrednosti.
Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours. 
Intravensko dana zoledronska kislina se odstranjuje iz telesa s trifaznim procesom: hitro dvofazno izginotje iz sistemskega krvnega obtoka z razpolovnima časoma t1/2α 0,24 ure in t1/2β 1,87 ure, ki mu sledi dolga faza izločanja s končnim razpolovnim časom izločanja t1/2χ 146 ur.
Patients were stratified with respect to duration of glucocorticoid use prior to randomisation (≤ 3 months versus > 3 months). 
Bolnike so stratificiratli v dve podskupini glede na trajanje zdravljenja z glukokortikoidi pred randomizacijo (≤ 3 mesece oziroma > 3 mesece).
For information on the infusion of Zoledronic acid Teva Generics, see section 6.6. 
Za informacije o infundiranju zdravila Zoledronska kislina Teva Generics glejte poglavje 6.6.
Other products containing zoledronic acid as active substances are available for oncology indications. 
Obstajajo druga zdravila, ki vsebujejo zdravilno učinkovino zoledronska kislina in se uporabljajo za onkološke indikacije.
Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans. 
Na podlagi teh rezultatov ni mogoče ugotavljati dejanskega vpliva zoledronske kisline na plodnost pri ljudeh.
It is currently unclear whether Zoledronic acid Teva Generics causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic acid Teva Generics. 
Zaenkrat ni jasno, ali to nepravilno bitje srca povzroča zdravilo Zoledronska kislina Teva Generics, kljub temu pa morate zdravniku sporočiti, če pri vas pride do takih simptomov po prejemu zdravila Zoledronska kislina
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Generics can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Generics administration 
Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zdravila Zoledronska kislina Teva Generics, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zdravila Zoledronska kislina Teva Generics.
Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. 
Redko se lahko pojavijo neobičajni zlomi stegnenice, še posebno pri bolnikih, ki so na dolgotrajnem zdravljenju osteoporoze.
Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men. 
Osteoporoza je bolezen, pri kateri kosti postajajo bolj porozne in krhke, in je pogosta pri ženskah po menopavzi, vendar se lahko pojavi tudi pri moških.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy 
Zdravljenje osteoporoze zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. 
Pri bolnikih, pri katerih se med difosfonatnim zdravljenjem razvije osteonekroza čeljusti, lahko stomatološka operacija poslabša stanje.
Zoledronic acid Teva Generics works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone. 
Zoledronska kislina Teva Generics deluje tako, da normalizira proces kostne pregradnje, omogoči tvorbo normalne kostnine in tako kostem povrne čvrstost.
No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects. 
Starejši bolniki (≥ 65 let) Prilagajanje odmerjanja ni potrebno, ker so vrednosti biološke uporabnosti, porazdelitve in izločanja iz telesa pri starejših bolnikih in mlajših preiskovancih podobne.
Following the menopause bone loss occurs, bones become weaker and break more easily. 
Zato po menopavzi pride do izgubljanja kostne mase, kosti postanejo bolj krhke in lomljive.